ERBB2 and cancer: These ERBB2/HER2 mutations are associated with resistance to lapatinib but are sensitive to neratinib, highlighting the importance of treating HER-mutated cancers with the appropriate HER-targeted drugs (Table 2, Supplementary table 3) [37, 38].